Donepezil is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease.
AULBIO has developed a monthly injectable dosage form of donepezil that reduces the frequency of treatment to improve the patient's compliance. As the results of pharmacokinetic study in SD rat, The AULBIO treated group maintained effective donepezil levels in rat plasma for one month. Based on the
results, a clinical trial is currently being prepared.